RARE
Price
$27.30
Change
-$0.71 (-2.53%)
Updated
Jul 24, 04:59 PM (EDT)
Capitalization
2.58B
7 days until earnings call
XFOR
Price
$1.82
Change
+$0.32 (+21.33%)
Updated
Jul 24, 04:59 PM (EDT)
Capitalization
10.77M
7 days until earnings call
Interact to see
Advertisement

RARE vs XFOR

Header iconRARE vs XFOR Comparison
Open Charts RARE vs XFORBanner chart's image
Ultragenyx Pharmaceutical
Price$27.30
Change-$0.71 (-2.53%)
Volume$46.3K
Capitalization2.58B
X4 Pharmaceuticals
Price$1.82
Change+$0.32 (+21.33%)
Volume$12.18K
Capitalization10.77M
RARE vs XFOR Comparison Chart in %
Loading...
RARE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
XFOR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Regeneron Pharmaceuticals (NASDAQ:REGN), Incyte Corp (NASDAQ:INCY), Moderna (NASDAQ:MRNA), Exelixis (NASDAQ:EXEL), Arrowhead Pharmaceuticals (NASDAQ:ARWR), BioCryst Pharmaceuticals (NASDAQ:BCRX), Adaptive Biotechnologies Corp (NASDAQ:ADPT), Sarepta Therapeutics (NASDAQ:SRPT), Novavax (NASDAQ:NVAX), Nektar Therapeutics (NASDAQ:NKTR).

Industry description

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

Market Cap

The average market capitalization across the Biotechnology Industry is 2.5B. The market cap for tickers in the group ranges from 58 to 309.36B. NONOF holds the highest valuation in this group at 309.36B. The lowest valued company is SEELQ at 58.

High and low price notable news

The average weekly price growth across all stocks in the Biotechnology Industry was 6%. For the same Industry, the average monthly price growth was 18%, and the average quarterly price growth was 29%. AAVXF experienced the highest price growth at 794%, while REPL experienced the biggest fall at -74%.

Volume

The average weekly volume growth across all stocks in the Biotechnology Industry was 8%. For the same stocks of the Industry, the average monthly volume growth was 2% and the average quarterly volume growth was 106%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 84
Price Growth Rating: 56
SMR Rating: 92
Profit Risk Rating: 95
Seasonality Score: -3 (-100 ... +100)

Market Cap

The average market capitalization across the group is 1.33B. The market cap for tickers in the group ranges from 10.77M to 2.65B. RARE holds the highest valuation in this group at 2.65B. The lowest valued company is XFOR at 10.77M.

High and low price notable news

The average weekly price growth across all stocks in the group was 1%. For the same group, the average monthly price growth was -31%, and the average quarterly price growth was -63%. RARE experienced the highest price growth at 3%, while XFOR experienced the biggest fall at -1%.

Volume

The average weekly volume growth across all stocks in the group was -37%. For the same stocks of the group, the average monthly volume growth was 205% and the average quarterly volume growth was 352%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 44
P/E Growth Rating: 100
Price Growth Rating: 95
SMR Rating: 56
Profit Risk Rating: 100
Seasonality Score: -25 (-100 ... +100)
VS
RARE vs. XFOR commentary
Jul 25, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is RARE is a Hold and XFOR is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 25, 2025
Stock price -- (RARE: $28.01 vs. XFOR: $1.50)
Brand notoriety: RARE and XFOR are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: RARE: 151% vs. XFOR: 140%
Market capitalization -- RARE: $2.58B vs. XFOR: $10.77M
RARE [@Biotechnology] is valued at $2.58B. XFOR’s [@Biotechnology] market capitalization is $10.77M. The market cap for tickers in the [@Biotechnology] industry ranges from $309.36B to $0. The average market capitalization across the [@Biotechnology] industry is $2.5B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

RARE’s FA Score shows that 0 FA rating(s) are green whileXFOR’s FA Score has 2 green FA rating(s).

  • RARE’s FA Score: 0 green, 5 red.
  • XFOR’s FA Score: 2 green, 3 red.
According to our system of comparison, XFOR is a better buy in the long-term than RARE.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

RARE’s TA Score shows that 4 TA indicator(s) are bullish while XFOR’s TA Score has 3 bullish TA indicator(s).

  • RARE’s TA Score: 4 bullish, 5 bearish.
  • XFOR’s TA Score: 3 bullish, 2 bearish.
According to our system of comparison, XFOR is a better buy in the short-term than RARE.

Price Growth

RARE (@Biotechnology) experienced а +2.56% price change this week, while XFOR (@Biotechnology) price change was -1.32% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +5.88%. For the same industry, the average monthly price growth was +18.15%, and the average quarterly price growth was +28.82%.

Reported Earning Dates

RARE is expected to report earnings on Nov 04, 2025.

XFOR is expected to report earnings on Jul 31, 2025.

Industries' Descriptions

@Biotechnology (+5.88% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
RARE($2.58B) has a higher market cap than XFOR($10.8M). RARE YTD gains are higher at: -33.420 vs. XFOR (-93.184). XFOR has higher annual earnings (EBITDA): 25.2M vs. RARE (-449.9M). RARE has more cash in the bank: 494M vs. XFOR (87M). RARE has less debt than XFOR: RARE (38.3M) vs XFOR (78M). RARE has higher revenues than XFOR: RARE (591M) vs XFOR (31.4M).
RAREXFORRARE / XFOR
Capitalization2.58B10.8M23,898%
EBITDA-449.9M25.2M-1,785%
Gain YTD-33.420-93.18436%
P/E RatioN/A0.71-
Revenue591M31.4M1,882%
Total Cash494M87M568%
Total Debt38.3M78M49%
FUNDAMENTALS RATINGS
RARE vs XFOR: Fundamental Ratings
RARE
XFOR
OUTLOOK RATING
1..100
5254
VALUATION
overvalued / fair valued / undervalued
1..100
75
Overvalued
13
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
10012
PRICE GROWTH RATING
1..100
9398
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

XFOR's Valuation (13) in the Biotechnology industry is somewhat better than the same rating for RARE (75). This means that XFOR’s stock grew somewhat faster than RARE’s over the last 12 months.

XFOR's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as RARE (100). This means that XFOR’s stock grew similarly to RARE’s over the last 12 months.

XFOR's SMR Rating (12) in the Biotechnology industry is significantly better than the same rating for RARE (100). This means that XFOR’s stock grew significantly faster than RARE’s over the last 12 months.

RARE's Price Growth Rating (93) in the Biotechnology industry is in the same range as XFOR (98). This means that RARE’s stock grew similarly to XFOR’s over the last 12 months.

RARE's P/E Growth Rating (100) in the Biotechnology industry is in the same range as XFOR (100). This means that RARE’s stock grew similarly to XFOR’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
RAREXFOR
RSI
ODDS (%)
Bullish Trend 2 days ago
79%
Bullish Trend 2 days ago
87%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
72%
Bullish Trend 2 days ago
78%
Momentum
ODDS (%)
Bearish Trend 2 days ago
72%
N/A
MACD
ODDS (%)
Bearish Trend 2 days ago
67%
Bullish Trend 2 days ago
79%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
75%
Bearish Trend 2 days ago
90%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
83%
Bearish Trend 2 days ago
90%
Advances
ODDS (%)
Bullish Trend 2 days ago
77%
N/A
Declines
ODDS (%)
Bearish Trend 10 days ago
80%
Bearish Trend 7 days ago
90%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
90%
N/A
Aroon
ODDS (%)
N/A
Bearish Trend 2 days ago
90%
View a ticker or compare two or three
Interact to see
Advertisement
RARE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
XFOR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
FLGT18.880.25
+1.34%
Fulgent Genetics
MVO6.03N/A
N/A
MV Oil Trust
TCBI88.26-1.17
-1.31%
Texas Capital Bancshares
CNP37.12-0.64
-1.69%
CenterPoint Energy
SEGG1.18-0.04
-3.28%
Lottery com Inc

RARE and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, RARE has been closely correlated with MREO. These tickers have moved in lockstep 66% of the time. This A.I.-generated data suggests there is a high statistical probability that if RARE jumps, then MREO could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To RARE
1D Price
Change %
RARE100%
+5.94%
MREO - RARE
66%
Closely correlated
+5.97%
VCYT - RARE
46%
Loosely correlated
+2.98%
NRIX - RARE
46%
Loosely correlated
+3.38%
CRNX - RARE
45%
Loosely correlated
+1.67%
TRDA - RARE
44%
Loosely correlated
+0.16%
More

XFOR and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, XFOR has been loosely correlated with XCUR. These tickers have moved in lockstep 34% of the time. This A.I.-generated data suggests there is some statistical probability that if XFOR jumps, then XCUR could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To XFOR
1D Price
Change %
XFOR100%
+0.67%
XCUR - XFOR
34%
Loosely correlated
+5.41%
SPHDF - XFOR
34%
Loosely correlated
N/A
CRDF - XFOR
31%
Poorly correlated
+9.72%
ABSI - XFOR
31%
Poorly correlated
-3.03%
ELDN - XFOR
29%
Poorly correlated
+2.70%
More